BNS Staff, writers and editors —

BioNews, the owner and publisher of this site, employs science writers and editors, most of whom have PhDs in the life sciences, as well as veteran journalists, who ensure stories are well-written and easy to understand. Our stories undergo a comprehensive fact-checking and editing process to confirm accuracy, objectiveness, and thoroughness in order to best serve our audience of patients and caregivers.

Articles by BioNews Staff

Q&A with Sanofi: Nexviazyme Safely Aids Muscle Strength in LOPD

Newly approved, Nexviazyme (avalglucosidase alfa) is a next-generation, alternative enzyme replacement therapy for late-onset Pompe disease patients starting at age 1. In clinical trials that supported the Aug. 6 approval by the U.S. Food and Drug Administration (FDA), meaningful improvements in respiratory muscle strength and mobility were evident in patients given…

FAQs About Lumizyme for Pompe Disease

Lumizyme (alglucosidase alfa) is an enzyme replacement infusion therapy by Sanofi Genzyme for people with Pompe disease. In the European Union, it is available under the brand name Myozyme. Here are answers to some frequently asked questions about this treatment. How does Lumizyme work? Lumizyme works to replace…